PTC Therapeutics Inc. (PTCT)
PTC Therapeutics Statistics
Share Statistics
PTC Therapeutics has 78.87M shares outstanding. The number of shares has increased by 2.83% in one year.
| Shares Outstanding | 78.87M |
| Shares Change (YoY) | 2.83% |
| Shares Change (QoQ) | 2.26% |
| Owned by Institutions (%) | 99.99% |
| Shares Floating | n/a |
| Failed to Deliver (FTD) Shares | 687 |
| FTD / Avg. Volume | 0.07% |
Short Selling Information
The latest short interest is 5.48M, so 6.95% of the outstanding shares have been sold short.
| Short Interest | 5.48M |
| Short % of Shares Out | 6.95% |
| Short % of Float | 10.68% |
| Short Ratio (days to cover) | 3.77 |
Valuation Ratios
The PE ratio is -9.55 and the forward PE ratio is -26.13. PTC Therapeutics's PEG ratio is 0.22.
| PE Ratio | -9.55 |
| Forward PE | -26.13 |
| PS Ratio | 4.3 |
| Forward PS | 2.7 |
| PB Ratio | -3.16 |
| P/FCF Ratio | -30.38 |
| PEG Ratio | 0.22 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for PTC Therapeutics.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.35, with a Debt / Equity ratio of -0.35.
| Current Ratio | 2.35 |
| Quick Ratio | 2.31 |
| Debt / Equity | -0.35 |
| Debt / EBITDA | -3.23 |
| Debt / FCF | -3.41 |
| Interest Coverage | -1.81 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $859,190.63 |
| Profits Per Employee | $-386,895.63 |
| Employee Count | 939 |
| Asset Turnover | 0.47 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | 176K |
| Effective Tax Rate | -0.05% |
Stock Price Statistics
The stock price has increased by 47.23% in the last 52 weeks. The beta is 0.58, so PTC Therapeutics's price volatility has been higher than the market average.
| Beta | 0.58 |
| 52-Week Price Change | 47.23% |
| 50-Day Moving Average | 50.44 |
| 200-Day Moving Average | 42.91 |
| Relative Strength Index (RSI) | 52.97 |
| Average Volume (20 Days) | 968,145 |
Income Statement
In the last 12 months, PTC Therapeutics had revenue of 806.78M and earned -363.3M in profits. Earnings per share was -4.73.
| Revenue | 806.78M |
| Gross Profit | 806.78M |
| Operating Income | -302.57M |
| Net Income | -363.3M |
| EBITDA | -120.46M |
| EBIT | -196.13M |
| Earnings Per Share (EPS) | -4.73 |
Balance Sheet
The company has 779.71M in cash and 389.3M in debt, giving a net cash position of 390.41M.
| Cash & Cash Equivalents | 779.71M |
| Total Debt | 389.3M |
| Net Cash | 390.41M |
| Retained Earnings | -3.65B |
| Total Assets | 1.71B |
| Working Capital | 784.55M |
Cash Flow
In the last 12 months, operating cash flow was -107.69M and capital expenditures -6.5M, giving a free cash flow of -114.19M.
| Operating Cash Flow | -107.69M |
| Capital Expenditures | -6.5M |
| Free Cash Flow | -114.19M |
| FCF Per Share | -1.49 |
Margins
Gross margin is 100%, with operating and profit margins of -37.5% and -45.03%.
| Gross Margin | 100% |
| Operating Margin | -37.5% |
| Pretax Margin | -45.01% |
| Profit Margin | -45.03% |
| EBITDA Margin | -14.93% |
| EBIT Margin | -37.5% |
| FCF Margin | -14.15% |
Dividends & Yields
PTCT does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Analyst Forecast
The average price target for PTCT is $60.5, which is 22.2% higher than the current price. The consensus rating is "Buy".
| Price Target | $60.5 |
| Price Target Difference | 22.2% |
| Analyst Consensus | Buy |
| Analyst Count | 13 |
Scores
| Altman Z-Score | -1.52 |
| Piotroski F-Score | 3 |